European Commission has designated oral decitabine and cedazuridine as orphan drugs for the treatment of Acute myeloid leukemia (AML)
Astex Pharmaceuticals, Inc. today announces that the European Commission (EC) has granted orphan-drug designation to the oral fixed-dose combination of decitabine and cedazuridine for the treatment of ...
Acute Myeloid Leukemia (AML): Global Incidence, Signs and Symptoms
[vc_row][vc_column][vc_custom_heading text="Acute Myeloid Leukemia (AML): Global Incidence, Signs and Symptoms" font_container="tag:h2|text_align:center" use_theme_fonts="yes"][/vc_column][/vc_row][vc ...
Kura Oncology Announces First Patients Dosed in Phase 2 Trial of Ziftomenib in NPM1-Mutant Acute Myeloid Leukemia
Kura Oncology Inc., a clinical-stage biopharmaceutical company dedicated to realizing the promise of precision medicines for cancer treatment, announced today that the first patients in its KOMET-001 ...